Canocapavir

CAS No. 2137847-19-7

Canocapavir( —— )

Catalog No. M35755 CAS No. 2137847-19-7

Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 454 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Canocapavir
  • Note
    Research use only, not for human use.
  • Brief Description
    Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
  • Description
    Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2137847-19-7
  • Formula Weight
    562.39
  • Molecular Formula
    C27H21BrFN5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 300 mg/mL (533.44 mM; Ultrasonic (<60°C)
  • SMILES
    C(CC=1C=C2C(=CC1)NC(=O)N2)N3[C@@H](C=4C(=NN(C4)C5=CC=C(Br)C=C5)C6=CC=C(F)C=C6)OCC3=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf?sfvrsn=8544ca1e_3&download=true
molnova catalog
related products
  • Alisol F

    Alisol F is a natural product from Alisma plantago-aquatica Linn and has many activities.Alisol F shows anti-inflammatory activities and liver protection through the inhibition of MAPK, STAT3, and NF-κB activation in vitro and in vivo, it suppresses iNOS induction.

  • Inarigivir ammonium

    Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.

  • Lagociclovir

    Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.